An interventional study of Photobiomodultion with Laser scanning and patellar mobilization with exercise therapy in Anterior Knee Pain, Photobiomodulation (PBM) and Laser Therapy, sponsored by New Ismailia National University. Enrolling by invitation at 1 site in Jordan. Open to female participants aged 14 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by New Ismailia National University · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to assess the augmented recovery in the adolescent females with patellar tendinopathy using Phot- Biomodulation
To investigate the effectiveness of photobiomodulation therapy in enhancing recovery among adolescent females diagnosed with patellar tendinopathy.
Primary Objective
To determine the effect of PBM on pain reduction and functional improvement compared with standard rehabilitation alone.
Secondary Objectives To evaluate the effect of PBM on tendon-related disability. To assess changes in knee function and physical performance. To evaluate the impact of PBM on health-related quality of life. To assess the sustainability of treatment effects during follow-up. Study Design
A prospective, randomized, controlled, parallel-group clinical trial.
Participants
Adolescent females aged 12-18 years diagnosed with patellar tendinopathy according to clinical examination and established diagnostic criteria.
Intervention Group
Participants will receive photobiomodulation therapy combined with a standardized exercise-based rehabilitation program.
Control Group
Participants will receive the same standardized rehabilitation program with either sham photobiomodulation or rehabilitation alone.
Outcome Measures
Primary Outcomes
Pain intensity measured using the Visual Analog Scale (VAS) or Numeric Pain Rating Scale (NPRS).
Functional disability measured using the Victorian Institute of Sport Assessment-Patella (VISA-P) questionnaire.
Secondary Outcomes
Knee functional performance tests. Quadriceps muscle strength. Patient-reported functional outcomes. Quality of life assessment.
10,054 studies on the registry are indexed under Pain; 1,649 are open to participants now.
This study's planned enrollment of 104 is above the median of 66 across 8,493 interventional studies indexed under Pain.
Browse Pain studies →New Ismailia National University is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients in the control group will receive therapeutic ultrasound, deep friction massage, patellar mobilization, and exercise program
Other: patellar mobilization with exercise therapy
patients in this group will receive photo biomodulation therapy, LASER scanning therapy, and exercise program as given to the control group
Device: Photobiomodultion with Laser scanning
The photobiomodulation intervention consists of applying low-level laser therapy to the anterior knee region using a calibrated laser device with predetermined wavelength, power output, and dosage parameters. The treatment aims to reduce pain, promote tissue healing, and improve functional outcomes. PBM sessions are administered in conjunction with a standardized exercise rehabilitation program throughout the treatment period.
Also known as: Exercise therapy
The intervention consists of therapeutic ultrasound applied to the anterior knee region using standardized treatment parameters, followed by patellar mobilization techniques performed by a trained therapist. The treatment aims to reduce pain, improve patellar mobility, enhance knee function, and facilitate participation in a structured exercise rehabilitation program.
Also known as: therapeutic ultrasound
knee pain
Will be measured by pressure algometer which is a handheld instrument used to objectively assess pressure pain threshold (PPT), and defined as the minimum amount of pressure that changes the sensation from pressure alone to the first feeling of pain. A high score means better improvement and vise versa.
Time frame: 12 weeks
Range of Motion
Knee joint range of motion will be assessed in degrees using a standard universal goniometer. Measurements of active knee flexion and extension will be recorded to evaluate joint mobility, identify functional limitations, and monitor changes following the intervention period. Increasing the Range of Motion means a better improvement.
Time frame: 12 weeks
Patients' Quality of Life
Will be measured by using The Pediatric Quality of Life Inventory scale and considered a standardized, validated questionnaire designed to measure health-related quality of life in children and adolescents aged 2 to 18 years. It evaluates the impact of health conditions on a child's physical, emotional, social, and school functioning. A high score means better improvement and vise versa. Minimum score = 0 and maximum = 100
Time frame: 12 weeks
Started Jul 2026 (actual). Primary completion is estimated for Oct 2026, 3 months after the start.
Of 3,731 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 3 months is below that.
Counting every sponsor, half of 3,830 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
New Ismailia National University